Interview with Richard Blackburn, Managing Director, Pfizer UK
As part of a panel discussion with Claudia Hammond of the BBC last year, you commented on the fairly poor relationship between the NHS and industry, and the need to…
Address: 198 High Holborn, London, UK, WC1V 7BD ,United Kingdom
Tel:
EMIG is the trade association in the UK that represents the interests of small to medium-sized pharmaceutical companies.
EMIG member companies range from start-ups, whose prime focus is R&D, to highly developed businesses delivering essential products to patients, while continuing to invest heavily in the fight against disease.
This rich blend of companies enables EMIG to uniquely understand and address the myriad challenges facing pharmaceutical innovation and commercialisation in the UK.
EMIG is a democratic organisation, with one vote for each full member company, irrespective of size.
EMIG enables pharmaceutical SMEs to have an influence on the policies that determine success or failure in the UK.
The EMIG deals with the following key issues:
Market Access Barriers
NHS Quality, Innovation, Productivity and Prevention
Generic substitution
Medicine Assessment Submission Costs
MHRA
Medicines Distribution
Shortage of Medicines
Code of Practice
Pharmaceutical Price Regulation Scheme (PPRS)
As part of a panel discussion with Claudia Hammond of the BBC last year, you commented on the fairly poor relationship between the NHS and industry, and the need to…
Together with Germany, the UK the highest generic penetration rate in Europe. Since you have been with the association since 1995 and obviously saw the great emergence of the generic…
What are the priorities on your agenda as the new head of ABPI considering the successes and difficulties the association has experienced in the past? If you look at the…
The UK has got around half of the public biotech companies and 21% of all entrepreneurial bioscience companies in Europe. From your perspective, can you explain what the key success…
AstraZeneca reported decrease in its global revenue for the first half of 2011 mostly due to adverse market conditions in the US. In this context, how has the company been…
Thank you for having us today! You have been chief executive of the Association since 1990 and obviously observed the evolution of the OTC market from close by. From your…
Given the heated debate over NHS reform and the new revised bill proposed by the government, what are you current priorities as President of the ABPI and how have these…
See our Cookie Privacy Policy Here
